SLC7A11 and neoplasm: RT suppresses SLC7A11, a member of solute carrier family 7 and factor in the glutamate cystine reverse transporter XC-, by activating the ataxia telangiectasia mutated gene, resulting in reduced cysteine uptake, reduced GSH synthesis, enhanced tumor lipid oxidation and ferroptosis, and improved tumor control (103).